Dan Schultz joins Greenleaf consulting firm
This article was originally published in The Silver Sheet
Executive Summary
Former CDRH Director Dan Schultz has joined Greenleaf Health's Washington, D.C., office as senior VP for medical devices and combination products, the consulting firm announced Jan. 6. Schultz left the device center in August after leading the center for five years ("The Silver Sheet" August 2009). Greenleaf has snagged several recently departed top FDA officials, including Taryn Fritz Warpole, former deputy chief of staff, who joined the firm in July, and former Commissioner Andrew von Eschenbach, who signed on as a senior advisor in March
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.